Tagged with EG

innovation The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his company is adapting its offering to mirror the changing health profile of the nation which is currently undergoing a transition from infectious and transmissible disease to chronic and lifestyle illnesses.…

Pain Latin America continues to be in the spotlight at Grünenthal. The managing director for Mexico explains how the company is strengthening its product portfolio, working with stakeholders to create more awareness about pain treatment and on the good path to hit USD 100 million sales within the next four years.…

Bayer Bayer Malaysia’s managing director, Thomas Steffen, discusses the key differences and opportunities offered by the Malaysian market and calls for more information to help the promotion of oral contraception in order to strengthen women’s role in society. As you are managing the pharmaceutical business in both Malaysia and Singapore, how…

innovation Recognizing the value of innovation is fundamental for the success of every pharmaceutical company operating in Korea. Lee Sang-Suk, CEO of the Korean Research-based Pharmaceutical industry Association (KRPIA), demonstrates the commitment of multinationals to Korea to help illustrate the benefits of innovation that Koreans can access.     What is…

regulation The Indian joint secretary for commerce and industry, interviewed at CPhI Worldwide 2014 in Paris, discusses India’s place in the global pharmaceutical landscape, and emphasizes the country’s contribution to the world’s health.   India has gone to great lengths at this CPhI conference to brand itself and show the world…

compliance The president of CETIFARMA, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discusses the tireless effort it has made to professionalize the compliance function in the industry as well as the growing importance of transparency and ethics in its relation with physicians and patients.  …

Deloitte In the second part of this interview, the managing partner of Deloitte Algeria sheds light on opportunity and risk in the Algerian pharma market. He explains the distorting effect of strict joint venture rules and outlines the many challenges in navigating Algeria’s regulatory and legal frameworks while at the same time…

consulting The managing partner of one of the “big four” consultancies speaks out about market entry strategies for Algeria and how Deloitte itself went about servicing the local pharmaceuticals industry among other thriving economic sectors. As a member of the “Big Four” professional services firms, what sort of offering does Deloitte…

chamber of commerce The European Chamber of Commerce in Korea (ECCK) was founded in 2012, in order to represent the interests of European businesses in Korea. Christoph Heider, secretary general of ECCK, discusses the initial challenges involved in establishing the chamber, as well as his outlook on the challenges and opportunities that the…

strategy Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and highlights the affiliate’s emphasis on its clinical research and its impact on Argentina’s healthcare environment.   What have been some…

orphan drugs Gabriela Pittis discusses the Argentinian healthcare system’s ability to diagnose, treat, and regulate rare diseases, and the country’s progress in further developing what is already the region’s most comprehensive system in this regard.   Is the Argentinian system able to reliably diagnose and treat rare diseases? “Rare diseases” is a…

Egypt The table below shows highlighted markets in the MENA region, and their performance in 2013. Saudi Arabia is the largest pharma market in the region, with Iraq as the fastest growing market.